Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
O75746
UPID:
S2512_HUMAN
Alternative names:
Araceli hiperlarga; Mitochondrial aspartate glutamate carrier 1; Solute carrier family 25 member 12
Alternative UPACC:
O75746; B3KR64; Q96AM8
Background:
The Electrogenic aspartate/glutamate antiporter SLC25A12, mitochondrial, also known as Mitochondrial aspartate glutamate carrier 1 and Araceli hiperlarga, plays a crucial role in mitochondrial function. It facilitates the exchange of aspartate and glutamate across the mitochondrial membrane, integral to the malate-aspartate shuttle, a key process in cellular energy production.
Therapeutic significance:
SLC25A12's involvement in Developmental and epileptic encephalopathy 39 with leukodystrophy, a severe early-onset epilepsy, underscores its therapeutic potential. Targeting this protein could lead to novel treatments for this and related neurological disorders.